We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
(-5.5%)
Cap. Flow
-$340M
Cap. Flow
% of AUM
-27.05%
Top 10 Holdings %
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$13.6M |
| 2 |
Gossamer Bio
GOSS
|
+$8.85M |
| 3 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$7.61M |
| 4 |
Celldex Therapeutics
CLDX
|
+$7.3M |
| 5 |
Black Diamond Therapeutics
BDTX
|
+$6.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$23.1M |
| 2 |
BioXcel Therapeutics
BTAI
|
+$17.3M |
| 3 |
Immunovant
IMVT
|
+$12M |
| 4 |
argenx
ARGX
|
+$11.4M |
| 5 |
Verastem
VSTM
|
+$7.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Solid Biosciences
SLDB
$794M
| $2.31M | 0.18% |
52,534
+16,597
| +46% | +$689K |
|
102
Acadia Pharmaceuticals
ACAD
$4.43B
| $2.23M | 0.18% |
+46,008
| New | +$2.21M |
|
|
ZYNE
103
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $2.18M | 0.17% |
+647,400
| New | +$3.06M |
|
|
BLUE
104
CALL
DELISTED
bluebird bio
BLUE
| $2.14M | 0.17% |
2,702
-2,702
| -50% | -$2.04M |
|
|
ADVM
105
PUT
DELISTED
Adverum Biotechnologies
ADVM
| $1.98M | 0.16% |
+9,480
| New | +$1.68M |
|
106
CALL
Moderna
MRNA
$21.8B
| $1.93M | 0.15% |
+30,000
| New | +$1.64M |
|
107
Altimmune
ALT
$552M
| $1.77M | 0.14% |
+165,000
| New | +$906K |
|
108
CALL
Fate Therapeutics
FATE
$286M
| $1.72M | 0.14% |
50,100
| – | – |
|
|
109
PUT
Fate Therapeutics
FATE
$286M
| $1.72M | 0.14% |
50,100
| – | – |
|
|
ICPT
110
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.7M | 0.14% |
35,500
-136,600
| -79% | -$10.6M |
|
111
PUT
Seres Therapeutics
MCRB
$46.8M
| $1.68M | 0.13% |
+17,615
| New | +$1.55M |
|
112
CALL
Axsome Therapeutics
AXSM
$11.2B
| $1.51M | 0.12% |
18,300
-356,700
| -95% | -$27.5M |
|
113
Achieve Life Sciences
ACHV
$659M
| $1.45M | 0.12% |
+182,927
| New | +$1.46M |
|
|
CLLS
114
Cellectis
CLLS
$277M
| $1.3M | 0.1% |
73,067
+42,139
| +136% | +$641K |
|
115
PUT
Minerva Neurosciences
NERV
$185M
| $1.25M | 0.1% |
43,288
+8,450
| +24% | +$496K |
|
|
116
CALL
Seres Therapeutics
MCRB
$46.8M
| $1.19M | 0.09% |
+12,500
| New | +$1.1M |
|
117
Mustang Bio
MBIO
$4.32M
| $1.13M | 0.09% |
475
| – | – |
|
118
ADMA Biologics
ADMA
$1.96B
| $1.11M | 0.09% |
378,574
-251,426
| -40% | -$722K |
|
|
OTIC
119
CALL
DELISTED
Otonomy, Inc.
OTIC
| $1.09M | 0.09% |
300,000
| – | – |
|
120
Avalo Therapeutics
AVTX
$965M
| $1.05M | 0.08% |
140
-56
| -29% | -$407K |
|
121
CALL
BridgeBio Pharma
BBIO
$15.7B
| $1.03M | 0.08% |
+31,500
| New | +$959K |
|
122
Delcath Systems
DCTH
$422M
| $964K | 0.08% |
+94,000
| New | +$759K |
|
|
SLNO
123
DELISTED
Soleno Therapeutics
SLNO
| $748K | 0.06% |
+22,453
| New | +$973K |
|
|
DBVT
124
DBV Technologies
DBVT
$799M
| $723K | 0.06% |
16,473
-6,338
| -28% | -$324K |
|
125
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $720K | 0.06% |
28,274
-330,650
| -92% | -$6.91M |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.
Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.
- Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
- Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
- Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
- Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
- Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
- Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
- Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.
Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.